Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. (2014).
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. (2006).

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. (2011).

Author(s): Martín­Moreno AM , Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML.

Based on the results of this study it was found that cannabidiol (CBD) has the ability to modulate the function of the microglial cell in vitro, inducing beneficial effects in an in vivo model of Alzheimer’s disease, thus indicating that CBD has the potential to represent a new therapeutic approach to treat this disease. View study